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Metastatic cutaneous squamous cell carcinoma (cSCC) is rare but deadly, leading to an 
estimated 3,932 to 8,791 deaths in the United States annually. Changes in microRNA 
(miRNA) expression have been found in every cancer and are associated with tumor 
development and metastasis. A Toland lab study investigated miRNA expression in 
cSCCs isolated from sites associated with metastasis (aggressive sites), cSCCs at sites 
with lower risk for metastasis (non-aggressive sites), and non-tumor skin tissue. miR-21, 
let-7g, miR-93, miR-22, and miR-31 showed different expression between aggressive 
and non-aggressive sites.  A literature search suggested that these miRNAs could play 
a role in the aggressiveness of tumors. miR-31 was one of the miRNAs that was 
upregulated in anatomical sites associated with cSCC metastasis. The upregulation of 
miR-31 at sites associated with metastasis led to the further investigation of its role in 
tumor and metastatic phenotypes in this study. Through literature and miRNA target 
database searches, we identified genes regulated or predicted to be regulated by miR-
31.  Many of these genes are part of the p38/MAPK pathway which has been reported 
to control some common metastatic phenotypes. Based on these studies, I 
hypothesized that an increase in miR-31 expression would lead to an increase in 
metastatic phenotypes via the p38/MAPK pathway.  The goal of this study was to 
evaluate metastatic phenotypes and determine whether miR-31 regulates p38/MAPK 
genes in keratinocyte or cSCC cells and if these genes were involved in any observed 
phenotypes. miR-31 expression was measured in HaCat (an immortalized keratinocyte 
cell line) and SRB-12 (a cSCC cell line) cells using quantitative real-time PCR (qPCR). 
Using transfection of miR-31 precursors or antagonists, miR-31 was overexpressed or 
inhibited in these cells. Western blot analysis was used to measure any post-translation 
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effects on candidate miR-31 targets. Migration and proliferation assays were performed 
to measure metastatic characteristics. Endogenous miR-31 was upregulated in SRB-12 
cells 2.6-fold (p-value=0.06) compared to HaCaT cells. qPCR analysis showed no 
significant expression differences between cells with or without miR-31 expression and 
the predicted miR-31 target genes: MAPKAPK2, DUSP7, STAT3, MAP3K1, MAPK14, 
MAP2K4, MEF2A, and CREB1. qPCR results showed a link between increased miR-31 
levels and decreased LIMK2 expression in the HaCaT cell line. MTT assays showed no 
conclusive differences in proliferation between HaCaT cells with or without miR-31 
expression. However, migration assays showed that HaCaT and SRB-12 cells 
transfected with miR-31 experienced gap closure before cells transfected with anti-miR-
31. In summary, increased miR-31 expression leads to an increase in the migration of 
HaCaT and SRB-12 cells, suggesting that miR-31 may contribute to this metastasis-
related phenotype. Of the target genes, we only observed a weak correlation between 
LIMK2 expression and miR-31. Future studies will determine if MAPK pathway gene, 
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CHAPTER 1: INTRODUCTION  
1.1 Cutaneous Squamous Cell Carcinoma  
Cutaneous squamous cell carcinoma (cSCC) is a form of skin cancer arising 
from keratinocytes. In Caucasians, it is the second most common form of skin 
cancer. [1] Incidence of cSCC has been rising in previous years; cSCC incidence 
has increased by 263% from the 1976-84 timeframe to the 2000-10 timeframe. [2] A 
frequent location of this cancer is on the head and neck; this could be due to 
increased exposure to UV radiation. [1] For example, in one study with 772 primary 
cSCC tumor samples, 96.5% of the tumors were located in a sun-exposed region on 
the head or neck. [3] Other factors that lead to a higher rate of cSCC are genetic 
predisposition, immunosuppression, and chemical carcinogen exposure. [1]  
Cutaneous squamous cell carcinoma is derived from actinic keratoses. [3-5] 
Actinic keratoses are cancer precursors found on sun damaged skin. They present 
as keratinocytes with abnormal nuclei and disorganized growth that leads to a 
thickened stratum corneum, the top layer of the epidermis. Mutations in genes that 
regulate the cell cycle- p53, p16, CDK4, STAT3- are thought to cause the precursor 
actinic keratoses to develop into primary cSCC and may also influence the 
development of metastatic cSCC. [5]  
Although the morbidity of cSCC is increasing, the mortality is generally low. In 
2020, only 0.002-0.004% of the U.S. white population died from cSCC. [6] However, 
the development of metastatic cSCC increases disease-associated mortality. 
Metastatic cSCC is rare but deadly, leading to an estimated 3,932 to 8,791 deaths in 
the United States each year. About 70% of cSCCs that metastasize to distal sites 
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lead to death. [5] Typical locations of cSCCs that become metastatic are the lip, ear, 
nose, temple and the front of the scalp. [1]   
1.2  miR-31 
microRNAs (miRNA) are non-coding RNAs that regulate gene expression. They 
are about 22 nucleotides long and typically interact with the 3’ untranslated region 
(UTR) of target mRNAs. miRNAs are known to degrade mRNAs, repress translation 
of proteins, and thus suppress gene expression. Although, under specific conditions 
they can also activate gene expression. [7,8] 
The main pathway of miRNA biogenesis is the canonical pathway (Figure 1). 
Primary miRNAs (pri-miRNA) are processed into precursor miRNAs (pre-miRNA), 
and finally transformed into mature miRNAs. Transcription of host genes lead to pri-
miRNAs. These pri-miRNAs are then cleaved by the enzyme Drosha at the hairpin 
structure to make pre-miRNAs. The pre-miRNAs move to the cytoplasm where the 
endonuclease Dicer removes the terminal loop to generate the mature miRNA. The 
mature miRNA is then loaded into the miRNA-induced silencing complex (RISC). 
This complex targets complementary sequences mRNA for degradation. Fully 
complementary sequences result in degradation of the mRNA. When some 
mismatches are present, which is the majority of interactions in animal cells, this will 
lead to the repression of translation and eventually degradation by other complexes. 
[7,8] 
Changes in microRNA expression have been found in almost every cancer. [10] 
Many studies have been done to evaluate miRNAs in cancer diagnosis and 
prognosis as well as potential therapies or therapeutic targets.  The majority of 
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miRNAs are found in the cell but some are located in extracellular fluids, like plasma, 
serum, saliva, cerebrospinal fluid, and urine. These circulating miRNAs can be used 
as biomarkers to detect diseases. [7] 
miR-31 can act like a tumor suppressor or oncogene depending on the cell type. 
In triple negative breast cancer, miR-31 is downregulated and can inhibit metastasis. 
[11] Head and neck SCC and colorectal cancer both show upregulation of miR-31 
compared to normal tissues. [12,13] In cSCC, miR-31 has been previously described 
to act as an oncomiR which is a miRNA associated with cancer, and it is upregulated 
in tumors. [12,14,15] miR-31 was previously shown to target genes that influence 
cell cycle, metabolism, apoptosis, and DNA repair including FIH and RhoBTB1. 
[12,14] Recent studies have presented miR-31 as a regulator of metastasis and 
metastatic phenotypes like migration, invasion, and colony formation. The ability of 
cells to multiply, form colonies, move out of the primary tumor site, and invade other 
tissues is a crucial part of metastasis. [15] While there has been a strong link 
between miR-31 and metastasis in many cancer types, including cSCC, there has 
been little research into the gene targets of miR-31 that lead to these phenotypes. 
 
1.3 p38/MAPK pathway  
The mitogen-activated protein kinase (MAPK) pathway has three familial 
subsets. These include the extracellular signal-regulated kinase (ERK), Jun kinase 
(JNK/SAPK) and p38 MAPK. [16] This is a complex signaling pathway with linkage 
to many genes as well as other pathways. Dysregulation of the MAPK pathway is 
not uncommon in cancers. The MAPK pathway in its simplest form is a protein 
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kinases cascade. An outside signal activates mitogen-activated protein kinase 
kinase kinases (MAPKKK) to phosphorylate and activate MAP kinase kinases 
(MAPKK) which then phosphorylate and activate MAP kinase (MAPK) that can then 
produce a biological response. [16] The different families of the MAPK pathway are 
defined based on the stimulus that triggers them into the cascade. The ERK 
pathway is activated by growth factors. The JNK pathway is activated by 
environmental stressors, inflammatory cytokines, and growth factors. The p38 
pathway is primarily stimulated by environmental stressors, like UV radiation, and 
inflammatory cytokines. [17] (Figure 2) 
The p38 pathway plays a role in many cellular responses that are important in 
cancer progression. These include apoptosis, differentiation, and proliferation. [18] 
This pathway can also induce metastasis by regulating important steps like invasion 
and epithelial to mesenchymal transition (EMT). EMT is caused by a downregulation 
of E-cadherin. Examples of p38 pathway gene products that suppress E-cadherin 
are TWIST1 and SNAIL in mammary and ovarian cells respectively. [19] During 
EMT, normal polarized epithelial cells that attach to the basement membrane of the 
cell are changed into mesenchymal cells that are able to mobilize throughout the 
body and differentiate into other types of cells. [20] Invasion is also an important part 
of metastasis. The cells need to be able to move out of their primary tumor site and 
into distant tissues for optimal growth. The p38 pathway has numerous targets that 
can affect this phenotype; for example, the LIMK1/2 genes are shown to be 




1.4  LIMK2  
The LIM kinase (LIMK) gene family consists of LIMK1 and LIMK2. Both of 
these genes are important for metastasis and share very similar genomic 
structure. The LIMKs regulate actin rearrangement in a cell by phosphorylating 
cofilin which inactivates it. [22] Cofilin works as a depolymerization agent and the 
inactivation of cofilin causes a change in actin remodeling. The increase in actin 
remodeling can promote the formation of cell pseudopodia, a part of the cell used 
for movement. [23]  
 The LIMK family has multiple pathways which leads to its activation and 
subsequent contributions to metastasis. In vascular endothelial growth factor A 
(VEGF-A) induced cells, LIMK1 was activated by MAPKAPK-2, part of the p38 
MAPK pathway. This activation led to actin reorganization and migration. [24] In 
colorectal cancer (CRC) cells, LIMK2 was downregulated in more aggressive 
forms of CRC while LIMK1 was upregulated. In this study, LIMK1 competed with 
LIMK2 to bind to beta-catenin in the Wnt/beta-catenin pathway. [25] Low 
expression of LIMK2 in CRC also advanced EMT-induced metastasis. [25] In 
pancreatic cancer cells, LIMK1 and LIMK2 knockdowns caused a decrease in 
metastasis and angiogenesis. [26] In another study, LIMK2 was activated by 
ROCK which is a downstream protein of the Rho family GTPases. [27] LIMK and 
the MAPK pathway also share a common link in the p21 activated kinase (PAK). 
PAK phosphorylates LIMK to activate it which in turn leads to suppression of 
Cofilin. [28] PAK also activates the MAPK pathway by phosphorylating Raf1 and 
Nuclear factor-κB. [29] LIMK activation is a complex process mediated by 
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multiple pathways but its importance to cytoskeleton remodeling has been found 
in many cellular abnormalities, including cancer. This connection with the 








Figure 1: Canonical pathway of miRNA biogenesis. Adapted from Hoffman 
et al., 2012 [9] Pri-miRNAs are cleaved by Drosha enzyme to make pre-miRNA 
which is exported to cytoplasm. In cytoplasm, Dicer enzyme cleaves pre-
miRNA into mature miRNA. Mature miRNA is loaded into miRNA-induced 





Figure 2. MAPK pathway and familial subsets. Adapted from Brutkiewicz, 2016 [18]. 
ERK1/2 is primarily stimulated by growth factors. JNK is stimulated by environmental 
stressors, inflammatory cytokines, and growth factors. P38 is primarily stimulated by 




CHAPTER 2: BACKGROUND 
2.1 Aggressive cSCC 
 Aggressive cutaneous squamous cell carcinoma (cSCC) metastasizes in 3.7-
5.4% of cases. [30] Features that are associated aggressive tumors with a tendency to 
metastasize include certain anatomical locations, increased depth and diameter, 
presence of perineural invasion, poor differentiation, infiltrative growth pattern, and 
history of recurrence. [31] The ear and lip are locations that exhibit an increase in 
metastasis with one 1992 study showing metastatic rates of 11% and 13.7% 
respectively. [32] The same study found a 30.3% and 45.7% metastatic rate for tumors 
with diameters greater than 2 cm and depths greater than 4mm. [33] Approximately 
32.8% of cSCCs that were poorly differentiated metastasized. [32] Finally, cSCCs with 
an infiltrative growth pattern had a 22.7% metastatic rate. [33] Only about 2-5% of 
cSCCs metastasize [34], but with over 700,000 new cases every year and over a 70% 
mortality rate of metastatic cSCC [6,35], it is imperative that aggressive cSCC is further 
studied in order to identify prognostic features and understand the metastatic process. A 
better understanding may lead to new therapeutic strategies targeting promoters of 
metastasis.  
2.2 Previous Toland Lab Study 
In a recently concluded project in the Toland lab, microRNA (miRNA) expression 
was evaluated in cSCCs isolated from sites associated with metastasis (aggressive 
sites), cSCCs at sites not associated with metastasis (non-aggressive sites), and non-
tumor skin tissue. [36] The most common sites for primary cSCCs that become 
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metastatic cSCC are on the ear, lip, and temple. [1] Primary cSCCs at other sites, like 
limbs and the trunk, are less likely to metastasize. Of the 800 miRNAs profiled, 
approximately 150 miRNAs were expressed in tumor or skin samples in preliminary 
NanoString nCounter miRNA studies. Of the 150 miRNAs, 37 miRNAs showed at least 
a two-fold difference between tumor sites. Literature searches found that five of the 
miRNAs were found in cancer or diseases associated with the skin. Further analysis to 
validate five miRNAs of interest (miR-21-5p, miR-31-5p, miR-22-3p, miR-93-5p, and let-
7g-5p) was done by quantitative real-time PCR (qRT-PCR) from the original 45 samples 
used for NanoString (18 aggressive sites, 15 non-aggressive sites, and 12 normal-
adjacent skin) as well as previously isolated RNA from 30 additional tissue samples (7 
aggressive sites, 14 non-aggressive sites, and 9 normal-adjacent skin).  I conducted the 
validation of the 30 additional samples not used in the original studies. miR-21, miR-22, 
and miR-31 were upregulated in the aggressive tumor sites, with miR-21 and miR-31 
showing statistically significant differences in expression when compared to normal 
tissue. These results were consistent with the preliminary NanoString nCounter boxplots 
(Figure 3). The upregulation of miR-31 from normal to aggressive sites of cSCC inspired 





Figure 3: Box plot of miR-31-5p NanoString data. Box plot of miR-31 expression as measured 
by NanoString in the original samples shows highest expression in tumors from aggressive sites, 











Figure 4: One-way ANOVA of miR-31-5p in Toland Lab study. One-way ANOVA 
data of miR-31 measured in normal skin, non-aggressive cSCC tumor sites, and 




CHAPTER 3: HYPOTHESIS AND SPECIFIC AIMS 
The main hypothesis of this study is that miR-31 is important for cSCC 
metastasis. After a literature and database search of miR-31 targets, the hypothesis 
was refined to include that miR-31 regulates genes in the p38/MAPK pathway that are 
responsible for characteristics of metastasis like cell migration and invasion.  
The specific aims of this study are stated below. 
1. To determine if there is a link between increased miR-31 expression and 
metastatic phenotypes. 
2. To determine if there is a link between miR-31 and genes expressed 













CHAPTER 4: MATERIALS AND METHODS 
4.1 HaCaT and SRB-12 cell lines 
HaCaT is a human immortalized keratinocyte cell line used to mimic normal cells. SRB-
12 is a cutaneous squamous cell carcinoma cell line derived from a human cSCC. Cell 
lines were tested for mycoplasma using the manufacturer’s protocol from the LookOut® 
Mycoplasma PCR Detection Kit (Sigma-Aldrich). Cell line identity was validated using 
the cell line authentication service of the OSU Genomics Shared Resource. HaCaT 
cells were grown in Dublecco’s Modified Eagle Medium (DMEM, Gibco) supplemented 
with 15% fetal bovine serum (FBS, Sigma), 1% penicillin streptomycin (Corning), and 
1% sodium pyruvate (Sigma). SRB-12 cells were grown in DMEM/F12 (1:1, Gibco) 
supplemented with 10% FBS and 1% penicillin streptomycin.   
4.2 Transfection  
In 24-well plates (1.9 cm2), HaCaT cells were plated with 200,000 cells per well and 
SRB-12 cells were plated with 150,000 cells per well one day prior to transfection. All 
transfections were done using Lipofectamine RNAiMAX. miR-31 was introduced to cells 
by transfection of hsa-miR-31 mirVana miRNA mimic and miR-31-3p expression was 
reduced using Anti-miR-31 miRNA inhibitor (Ambion). According to the manufacturer’s 
RNAi Transfection protocol, 50 µl of miRNA-lipid complex was added to a final volume 
of 500 µl per well. Cells were harvested one day after transfection.  
4.3 Identification of Genes of Interest and Primer Design 
Through database searches of miR-31, possible targets of miR-31 were identified. The 
databases used were miRWalk 3.0, miRDB, and Target Scan 7.0. Additional literature 
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searches led to the formation of the preliminary list of genes that were examined in this 
project. Those genes included: MAPKAPK2, DUSP7, STAT3, MAP3K1, MAPK14, 
MAP2K4, MEF2A, CREB1, and LIMK2. The genes chosen were either included in the 
p38/MAPK pathway or were related to the pathway. The role of p38/MAPK in metastatic 
phenotypes made this pathway of particular interest. [16,19] The common link of UV 
radiation activating the p38/MAPK pathway and playing an important role in cutaneous 
squamous cell carcinoma also sparked inquiry into the connection between cSCC 
metastasis, the p38/MAPK pathway, and miR-31. [1,5,17]  
SYBR Green Primers for qRT-PCR were designed based on previous primers found in 
literature (Table 1). [37-45]  
4.4 Quantitative Real-Time PCR  
RNA was extracted from transfected cells using RiboZol RNA Extraction Reagent 
(Amresco) according to the manufacturer’s recommended protocols. cDNA for qRT-
PCR of target genes of interest was made using 1ug of RNA and the iScript cDNA 
Synthesis Kit (BioRad). cDNA for miR-31 was made using TaqMan Advanced miRNA 
Assays kits (ThermoFisher). miR-31 expression was normalized using RNU6B, a low-
expressed reference gene. Relative Quantification Fast SYBR Green qPCR was used 
to measure the candidate miR-31 target genes of interest: LIMK2, MAPKAPK2, DUSP7, 
STAT3, MAP3K1, MAPK14, MAP2K4, MEF2A, and CREB1. GAPDH was used to 
normalize for gene expression.  Relative Quantification Fast TaqMan qPCR was used to 
evaluate the impact of miR-31 on genes of interest, LIMK2, MEF2A, and DUSP7 with 
PrimeTime Standard qPCR 5’ FAM 3’ ZEN™/Iowa Black®  nuclease assays (Integrated 
DNA Technologies). HPRT1 was used to normalize TaqMan data. A no-RT control was 
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used for each sample and a no template control was used for each primer.  5 µL 
PrimeTime™ Gene Expression 2X Fast Master Mix (Integrated DNA Technologies), 2.5 
µL of cDNA, and 2.5 µL probe mix was used for each 10 µL qRT-PCR reaction a 384 
well plate. All qPCR was performed in triplicate. Samples were processed by the OSU 
Genomics Shared Resource.  
The gene expression relative to the control gene was quantified using the formula: 
2∆Ct*100. ∆Ct was calculated by control gene expression-target gene expression.   
4.5 Proliferation Assay 
The MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Cell 
Proliferation Kit I and procedure (Roche) was used to measure cell proliferation in 
HaCaT cells.  One day post-transfection with miR-31 mimic or inhibitor, cells were 
harvested using 0.25% trypsin (Corning), manually counted using trypan blue and a 
hemocytometer, and plated in quadruplicate in a 96 well plate with 4,000 cells per well. 
After a 24-hour incubation period, the kit’s MTT labeling reagent was added and the 
cells were incubated for an additional 4 hours. The solubilization agent was added and 
after overnight incubation, absorbance at 550nm and 670nm was recorded on a 
spectrophotometer. 0, 24, and 48 hour post incubation with MTT time points were 
recorded. Cells were incubated at 37°C and 5% CO2 throughout the assay.   
MTT data was analyzed by A550nm – reference A670nm. The average blank absorbance 
was subtracted from the A550nm – A670nm value. These values were then averaged across 
the four wells per sample. Fold change was determined by dividing average value for 
each variable at 24 or 48 hours by the average value at hour 0.   
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4.6 Western Blot Analysis 
HaCaT cells were harvested 24 hours post-transfection and protein was extracted using 
a 1:25 solution of 25X protease inhibitor and RIPA buffer. Thirty µg of protein was run 
on 10% SDS-PAGE gels by electrophoresis for 90 minutes at 150 volts in 1x Running 
Buffer (25 mM Tris Base, 38 mM glycine, 0.1% SDS, ddH2O). Protein was transferred to 
nitrocellulose membranes, (GE Healthcare Life Sciences) at 90 volts for 70 minutes in 
1x Transfer Buffer (25 mM Tris Base, 190 mM glycine, ddH2O). The membrane was 
blocked in 5% milk in TBST (phosphate-buffered saline with 0.01% Tween 20) for 1 
hour. A 1:1000 dilution of the primary antibody in 5% milk in TBST was added to the 
membrane and incubated at 4°C overnight. Three 15 min TBST washes were done, 
followed by a 2 hour incubation with secondary antibody at room temperature. A 1:5000 
anti-rabbit secondary antibody (GE Healthcare UK Limited, NA934V) was used for 
phoso-CREB (Cell Signaling Technology, 9198) and p44/42 MAPK primary antibodies 
(Cell Signaling Technology, 9102). A 1:1000 anti-mouse secondary antibody (Jackson 
ImmunoResearch Laboratories, 115-035-003) was used for the STAT3 primary antibody 
(Cell Signaling Technology, 9139). GAPDH was used as a loading control (Santa Cruz 
Biotechnology, 25778). Following three washes, the SuperSignal West Pico 
Chemiluminescent Subrate Kit (ThermoFisher) was used to help visualize the western 
blot in a LI-COR Odyssey Fc Imager. Image analysis was performed in ImageJ.  
4.7 Migration Assay 
Migration Assays were performed with the HaCaT and SRB-12 cell lines. Cells 
transfected with miR-31 mimic and miR-31 inhibitor were harvested from 24-well plates 
at 24 hours post-transfection. Seventy µL of cells in 1% FBS media was added to each 
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well in a 2 well Culture-Insert (ibidi) placed in a 35mm x 10 mm culture dish. HaCaT 
cells were plated at 100,000 per well and SRB-12 cells were plated at 75,000 cells per 
well. The Culture-Insert was removed 24 hours later. Pictures were taken under a 
Fluorescent Cell Imager every 4 hours. Cells were incubated at 37°C and 5% CO2 
throughout the assay. Each variable was tested in duplicate and the experiment was 




Table 1. Published SYBR Green primers for candidate mir-31 target genes. 
Gene SYBR Green Primer 
LIMK37  Forward: 5′-GGGGCATCATCAAGAGCA-3′  
 Reverse: 5’-GAGGACTAGGGTGGTTCAG-3’ 
MAPKAPK238 Forward: 5’-CAGCAGTTCCCGCAGTTC-3’  
Reverse: 5’-CGAATTTCTCCTGGGTCCTC-3’  
DUSP739 Forward:5′–TCATTGACGAAGCCCG–3′ 
Reverse:5′–GCGTATTGAGTGGGAACA–3′ 
STAT340 Forward: 5’ -GCTTTTGTCAGCGATGGAGT-3’ 
Reverse: 5’ -ATTTGTTGACGGGTCTGAAGTT-3’ 
MAP3K141 Forward: 5’-CACGAATGGTTGGAAAGGAGAA-3’ 
Reverse:5’-AGATCCATCTCCTTTAACTGGGATT-3’ 
MAPK1442 Forward: 5’-GAGAGGCCCACGTTCTACC-3’ 
Reverse: 5’-CGTAACCCCGTTTTTGTGTCA-3’ 
MAP2K443 Forward:5′-GATGAATCCAAAAGGCCAAA-3′  
Reverse:5′-TCAATCGACATACATGGGAGAG-3′ 
MEF2A44  Forward: 5’-TCAAGCCACACAACCTCTTG-3’ 
Reverse: 5’-CAGCATTCCAGGGGAAGTAA-3’ 







CHAPTER 5: RESULTS 
5.1 miR-31 is upregulated in SRB-12 and COLO-16 compared to HaCaT 
To determine the level of expression of miR-31 in 3 human skin cell lines, RT-qPCR 
was performed. miR-31 expression was measured in HaCaT- an immortalized human 
kertatinocyte cell line, SRB-12- a human cSCC cell line, and COLO-16- a human cSCC 
cell line. There was a 3.0-fold change in miR-31 expression between HaCaT and 
COLO-16 cell lines (p-value=0.0078). There was a 2.6-fold difference in expression 
between SRB-12 and HaCaT cells, but this was not statistically significant (p-
value=0.06) (Figure 5). The higher expression of miR-31 in cSCC cells indicates that it 
plays a role in cancer phenotypes.  
5.2 miR-31 has multiple target genes that are associated with p38/MAPK pathway 
Gene targets of miR-31-5p were identified using the following miRNA databases: 
miRWalk 3.0, miRDB, and Target Scan 7.0. miR-31 targets were narrowed down by 
literature search looking for genes with expression in skin and association with the 
p38/MAPK pathway. MAPKAPK2, DUSP7, STAT3, MAP3K1, MAPK14, MAP2K4, 
MEF2A, CREB1, and LIMK2 were the genes chosen to be investigated. [24, 46-54] 
(Table 2) 
5.3 Multiple genes of interest show no trends in HaCaT cells transfected with miR-
31 mimic and inhibitor 
To investigate role of miR-31 in regulating target genes of interest, i.e. MAPKAPK2, 
DUSP7, STAT3, MAP3K1, MAPK14, MAP2K4, MEF2A, LIMK2, and CREB1, SYBR 
Green primers targeting the genes were first tested on cDNA from HaCaT, SRB-12, and 
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COLO-16 cells. The LIMK2, MEF2A, and DUSP7 SYBR Green primers failed to 
generate clean SYBR green dissociation curves or to result in detectable product; thus, 
TaqMan PrimeTime nuclease assays of these 3 genes were used for subsequent qPCR 
analysis. 
HaCaT cells were transfected with miR-31 mimic, anti-miR-31 inhibitor, a mock control, 
and a no transfection control. RNA was harvested at 24, 48, and 72 hours. miR-31 
expression was measured to test the efficiency of each transfection before measuring 
gene expression (Figure 6A,B). SYBR Green qPCR was used to measure the 
expression of these initial genes of interest. Genes MAPKAPK2, STAT3, MAP3K1, 
MAPK14, MAP2K4, and CREB1 showed no trend or significant difference between 
transfections (Figure 7A-F). This indicates that these genes are not regulated by miR-
31. 
TaqMan qPCR was used to test level of expression of genes LIMK2, MEF2A, and 
DUSP7 in HaCaT cells. HaCaT cells were transfected with miR-31 mimic, miR-31 
inhibitor, a mock control, or a no transfection control. RNA was harvested at 24, 48, and 
72 hours post-transfection. DUSP7 showed no trend or significant difference between 
transfections (Figure 8A). LIMK2 and MEF2A showed trends of cells transfected with 
miR-31 mimic having lower gene expression than cells transfected with anti-miR-31 
inhibitor (Figure 8B,C). MEF2A had a non-significant 1.3-fold decrease between miR-31 
and anti-miR-31 at 48-hours post-transfection. LIMK2 had a non-significant 1.3-fold 
decrease between miR-31 and anti-miR-31 in the 24-hour transfection and a non-
significant 1.6-fold decrease in the 48-hour transfection. A second experiment showed a 
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similar trend of decreased of LIMK2 in HaCaT cells transfected with miR-31 mimic, miR-
31 inhibitor, a mock control, and a no transfection control at 24 and 48 hours.  
5.4 LIMK2 expression is downregulated in HaCaT cells transfected with miR-31 
LIMK2 expression was measured by qPCR in HaCaT cells transfected with miR-31 
mimic, miR-31 inhibitor, a mock control, or a no transfection control. Expression was 
measured relative to a HPRT1 control. After two qPCR experiments, a non-significant 
trend of lower LIMK2 expression was observed in the miR-31 transfected cells relative 
to the anti-miR-31 transfected cells with a 1.7-fold change. A third experimental run 
showed a change in trend with higher LIMK2 expression in the miR-31 transfected cells 
relative to the anti-miR-31 HaCaT cells. An average of the three qPCR plates showed a 
1.2-fold increase in LIMK2 in the anti-miR-31 cells compared to the miR-31 in the 24-
hour transfection. There was no fold change between miR-31 and anti-miR-31 
transfected cells in the 48-hour HaCaT transfection (Figure 9). When combining data 
across experimental plates, there was not a significant decrease in LIMK2 expression in 
the miR-31 transfected cells. 
5.5 STAT3 protein expression is upregulated in miR-31 transfected HaCaT cells 
To test for translational effects of genes related to the MAPK pathway, western blot 
analysis was conducted on HaCaT cells 24-hours post-transfection. HaCaT cells were 
transfected with miR-31 mimic, anti-miR-31 inhibitor, mock, or no transfection controls. 
STAT3, phoso-CREB, and p44/42 MAPK antibodies were used to measure protein 
expression in these cells. Phospho-CREB showed no detectable expression. STAT3 
protein was upregulated 2.1-fold and 3.3-fold in miR-31 transfected cells compared to 
anti-miR-31 and mock transfected cells, respectively (Figure 10). p44/42 MAPK 
28 
 
expression showed no significant differences between transfection types (Figure 11). All 
quantification of staining was done in ImageJ.  As upregulation is not expected for a 
direct microRNA target, no additional experiments were done looking at STAT3. 
 
5.6 miR-31 has no effect on cell proliferation in HaCaT cells  
To determine the effects of miR-31 on cell proliferation, HaCaT cells were transfected 
with miR-31 mimic, anti-miR-31 inhibitor, mock, or no transfection controls. Proliferation 
was measured at 0, 24, and 48 hour post-transfection time points via an MTT assay. 
There was a significant difference between the optical density in miR-31 mimic and 
mock (p-value<0.0001) and miR-31 mimic and no transfection wells (p-value=0.0002) at 
hour 48 (Figure 12). There was no significant difference between miR-31 mimic and 
anti-miR-31 transfected cells. miR-31 transfected cells exhibited a 3.2-fold change 
between 0 and 48 hours. Anti-miR-31 transfected cells exhibited a 4.1-fold change 
between hour 0 and 48. Mock transfected cells showed a 4.5-fold change between 0 
and 48 hours. No transfection control cells had a 4.6-fold change between hour 0 and 
48. These results suggest that miR-31 does not play a role in cell proliferation.  
5.7 miR-31 does not regulate LIMK2 expression in SRB-12 cells 
After establishing a possible association of LIMK2 with miR-31 in HaCaT cells, LIMK2 
expression was measured in cSCC SRB-12 cells transfected with miR-31 mimic, anti-
miR-31 inhibitor, mock, or no transfection controls. LIMK2 expression was measured by 
qPCR 24-hours and 48-hours post-transfection. Each transfection and qPCR 
quantification was performed in triplicate. There was no significant difference between 
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transfection types (Figure 13). These results suggest that miR-31 does not regulate 
LIMK2 mRNA levels in SRB-12 cells.  
5.8 miR-31 promotes cell migration 
To determine if miR-31 affects cell migration, HaCaT and SRB-12 cell lines were 
transfected with miR-31 mimic, anti-miR-31 inhibitor, or mock. 24-hours post-
transfection cells were placed in a 2 well Culture-Insert and subjected to a migration 
assay. Twenty-four hours after placing the cells, the insert was removed and closure of 
the gap left from the insert was observed over a 24-hour period. HaCaT cells exhibited 
the most gap closure in miR-31 mimic transfected cells at the end of the 24-hour period 
(Figure 14). They also showed the most closure at the 8-hour time point. In HaCaT 
cells, the anti-miR-31 transfected cells displayed the least amount of closure after 24 
hours. Mock cells had an intermediate amount of closure (Figure 14). SRB-12 miR-31 
mimic transfected cells also showed more closure after 24 hours, although not as much 
as HaCaT cells. Mock and anti-miR-31 transfected cells showed similar amounts of 





Table 2: Gene targets of miR-31-5p and their role in p38/MAPK pathway 





1 Activated by MAPKAPK2 to 
phosphorylate ANXA146; forms 
lamellipodia for cell migration24 
MAPKAPK2 1 P38 activates/ phosphorylates 
gene to phosphorylate HSP27 
which has a role in inhibition of 
apoptosis and actin cytoskeletal 
remodeling47 
DUSP7 2 dual-specificity protein 
phosphatase, DUSP inactivates 
p38 dephosphorylates activation 
loop, chosen because high in 
skin48  
STAT3 1 Transcription factor activated by 
p38, regulates cell growth, 
apoptosis, immune response, and 
DNA damage response49 
MAP3K1 1 Regulates cell migration and pro-
survival signaling, loss of gene 
expression reduces cell migration 
and invasion and delays 
metastasis50  
MAPK14 2 Another name for p38α, activated 
by environmental stress and pro-
inflammatory cytokines, regulates 
cell proliferation, differentiation, 
migration, and survival51 
MAP2K4 1 Tumor suppressing gene52 
MEF2A 0 (1 in coding region) Found in molecular mechanisms 
of cancer, actin cytoskeletal 
signaling53 
CREB1 0 (1 in 5’UTR 1 in coding 
region 





Figure 5: Fold difference in miR-31 expression between HaCaT, SRB-12, and 
COLO-16 cell lines. miR-31 was upregulated in SRB-12 2.6-fold compared to HaCaT 
(p-value=0.06). A significant difference in expression between HaCaT and COLO-16 









Figure 6: miR-31 expression post-transfection. HaCaT (A) and SRB-12 (B) cells 
were transfected with miR-31 mimic (blue), anti-miR-31 inhibitor (red), mock (green), 
or no transfection (purple) prior to functional studies. miR-31 expression was 
measured 24 and 48 hours post-transfection. RNU6B was used as a loading control 
to normalize between samples. Fold-change was found relative to no transfection, 





Figure 7: qPCR results from genes tested with SYBR Green primers. HaCaT cells were transfected with 
miR-31 mimic (blue), anti-miR-31 inhibitor (red), mock (green), and no transfection (purple). Gene 
expression was measured at 24, 48, and 72-hours post-transfection. MAP3K1 (A), MAPKAPK2 (B), 
MAPK14 (C), STAT3 (D), MAP2K4 (E), and CREB1 (F) showed no consistent trend amongst time points 
and did not display the expected lower expression in miR-31 mimic transfected cells. GAPDH was used as a 















































































































































































































































































































































































































































































































































Figure 8: qPCR results from genes tested with 
PrimeTime TaqMan Primers. HaCaT cells were 
transfected with miR-31 mimic (blue), anti-miR-31 
inhibitor (red), mock (green), or no transfection 
(purple). Gene expression was measured at 24, 
48, and 72-hours post-transfection.  DUSP7 (A) 
showed no trend or significance between 
transfection types. LIMK2 (B) and MEF2A (C) 
showed non-significant trends of cells transfected 
with miR-31 mimic having lower gene expression 
than cells transfected with anti-miR-31 inhibitor. 
These results were relatively consistent between 
the 24 and 48-hour time points. HPRT1 was used 
as a control to normalize gene expression between 



































































































































































































































































Figure 9: Fold differences in LIMK2 expression for HaCaT. LIMK2 expression was measured by 
qPCR in HaCaT cells transfected with miR-31 mimic (blue), anti-miR-31 (red), mock (green) or no 
transfection (purple) 24- and 48-hours post-transfection.  HPRT1 was used to normalize for 
expression. There was no significant difference between transfection types. qPCR was performed in 




































































miR-31 anti mock no transfection
Ratio of STAT3/GAPDH in Western 
Blot Analysis
Figure 10: STAT3 is upregulated in miR-31 mimic transfected HaCaT cells. A. Western blot image 
taken in a LI-COR Odyssey Fc Imager.  B. STAT3 was upregulated 2.1-fold in miR-31 mimic transfected 
cells compared to anti-miR-31 transfected cells and 3.3-fold compared to mock transfected cells. Bands 


































Ratio of p42/ GAPDH in Western 
Blot Analysis
Figure 11:  p44/42 MAPK showed no difference between transfection types.  (A) miR-31 mimic, anti-miR-31 
inhibitor, mock, or no transfection HaCaT cells showed no significant difference in p44/42 MAPK protein 
expression as measured by western. There was slightly higher expression of p42 (B) compared to p44 (C) after 






Figure 12: Effect of miR-31 on cell proliferation. Cell Proliferation was measured at 0, 24, and 48 hours 
after transfection in HaCaT cells transfected with miR-31 mimic (blue circle), anti-miR-31 (red square), mock 
(green upright triangle), or no transfection (purple downward triangle). At 48 hours, there was a significant 
difference between miR-31 and mock (p-value<0.0001) and miR-31 and no transfection (p-value=0.0002). 
Proliferation was measured in quadruplicate at each time point. ***=p-value<0.001, ****=p-value<0.0001 
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Figure 13: Fold differences in LIMK2 expression for SRB-12. LIMK2 expression was measured by qPCR 
in SRB-12 cells transfected with miR-31 mimic (blue), anti-miR-31 (red), mock (green), or no transfection 
(purple) 24 and 48 hours post-transfection.  HPRT1 was used to normalize for expression. There was no 
significant difference between transfection types. qPCR was performed in triplicate; results shown are the 















































Figure 14: Migration assay after 24-hour transfection of HaCaT. miR-31 mimic transfected cells (top row) had the 
most migration after 24 hours, followed by mock (third row), and anti-miR-31 transfected cells (second row). Migration 






Figure 15: Migration assay after 24-Hour transfection of SRB-12. SRB-12 miR-31 mimic transfected cells showed 
the most amount of closure after 24 hours. Mock and anti-miR-31 transfected cells showed similar amounts of 
closure at the 8 and 24-hour time points. Migration assays were performed in triplicate with duplicates of transfection 
type in each assay. Red lines indicate border of gap between cells. 
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CHAPTER 6: DISCUSSION 
 Cutaneous squamous cell carcinoma is the second most common form of skin 
cancer in the Caucasian population [1]. Metastatic cSCC is rare, but with cSCC 
incidence on the rise and the high mortality of aggressive cSCC, studying the 
development of metastasis in cSCC is a worthy endeavor. Past studies with microRNAs 
in the Toland lab sparked further inquiry in this study into miR-31’s role in metastatic 
cSCC. 
The main hypothesis of this study was that miR-31 is important for cSCC 
metastasis. After a literature and database search of miR-31 targets, the hypothesis 
was refined to include that miR-31 regulates genes in the p38/MAPK pathway that are 
responsible for characteristics of metastasis and tumor characteristics like cell migration 
and invasion. There were two specific aims of this study: 
1. To determine if there is a link between increased miR-31 expression and 
metastatic phenotypes. 
2. To determine if there is a link between miR-31 and genes expressed in the 
p38/MAPK pathway.  
6.1 miR-31 is upregulated in cSCC cell lines 
After quantification of miR-31 by qPCR, I found that miR-31 has higher expression in 
cSCC cell lines, SRB-12 and COLO-16, as compared to HaCaT cells. HaCaT cells are 
human immortalized keratinocytes that model a normal, non-cancerous cell line. The 
greater expression of miR-31 in cell lines derived from tumors is consistent with my 




6.2 LIMK2 expression is downregulated in HaCaT cells transfected with miR-31  
Nine genes associated with the p38/MAPK pathway were investigated in this study. 
Genes were chosen because they were predicted to have miR-31 binding sites and an 
association with the p38/MAPK pathway.  MAPKAPK2, DUSP7, STAT3, MAP3K1, 
MAPK14, MAP2K4, MEF2A, LIMK2, and CREB1 expression were measured by qPCR 
in HaCaT cells. Results of these experiments showed no differences in expression of 
MAPKAPK2, DUSP7, STAT3, MAP3K1, MAPK14, MAP2K4, or CREB1 between cells 
transfected with miR-31 or anti-miR 31. MEF2A and LIMK2 showed 1.3-fold and 1.6-fold 
lower expression in miR-31 mimic transfected cells compared to the anti-miR-31 
transfected cells, respectively (Figure 8). This suggests that miR-31 may target MEF2A 
and LIMK2 mRNAs for degradation. [7,8] miR-31 has mismatches present in the binding 
site of the 3’ UTR of LIMK2, which could lead to miRNA repressing translation of LIMK2 
followed by mRNA degradation [8]. Due to its binding sites in the 3’ UTR and higher 
expression compared to MEF2A, LIMK2 was further investigated with two subsequent 
transfections and qPCRs to validate the trend shown. Initially, LIMK2 showed a trend of 
1.7-fold lower expression in miR-31 transfected cells compared to anti-miR-31 
transfected cells. On the third experimental replicate, the association between lower 
LIMK2 expression and miR-31 expression was no longer observed (Figure 9). This 
change in results could be due to HaCaT cells with a higher passage number being 
used at this stage in the study.  
LIMK2 functions as a regulator of actin remodeling, which can play a role in cell motility 
[22]. With a hallmark of metastasis being movement of cancerous cells to different 
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regions of the body, cell motility influenced by LIMK2 could play a role in metastasis. In 
colorectal cancer, aggressive tumors have decreased LIMK2 expression and an 
upregulation of miR-31. [13,24,25] The HaCaT keratinocyte cell line used in this study 
initially exhibited a similar tendency when transfected with miR-31; thus giving more 
indication that miR-31, LIMK2, and aggressive cancer phenotypes might be connected 
in the development of metastatic cSCC.  
6.3 miR-31 promotes migration phenotype 
The primary aim of this study was to investigate the role of miR-31 in metastatic 
phenotypes. Cell proliferation and migration were the two phenotypes evaluated.  There 
was no evidence that miR-31 affects cell proliferation as measured by MTT assay 
(Figure 12). Triplicate migration assays, each containing technical duplicates of each 
transfection type, showed that miR-31 influences cell migration. In both HaCaT and 
SRB-12, miR-31 transfected cells had the most gap closure after 24 hours. In HaCaT 
cells, the anti-miR-31 had the least amount of closure and mock cells had an 
intermediate amount of closure after 24 hours. In SRB-12, the mock and anti-miR-31 
had very similar amounts of gap closure after 24 hours. In a 2014 study, Wang et al. 
found similar results in miR-31 transfected UT-SCC-7, a SCC cancerous cell line, and 
scratch wound assays. [15]   
While the migration phenotype is promoted by miR-31, there may be different 
mechanisms behind this in each cell lines. SRB-12 cells did not have as pronounced 
differences in migration between transfection types. These cells also showed no 
conclusive link between miR-31 and LIMK2. On the other hand, HaCaT cells showed a 
greater migration and a noticeable difference in migration between the miR-31 mimic, 
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anti-miR-31, and mock transfection types. Decreased LIMK2 expression could be 
producing a more exaggerated migration- one comparable to decreased LIMK2 
expression leading to more aggressive tumors and EMT-induced metastasis in 
colorectal cancer. [24,25] 
6.4 Study Strengths and Limitations 
The scientific rigor was the main strength of this study. The transfections, qPCR 
quantification, and migration assays were all performed in triplicate. Each experiment 
contained biological replicates as well. The use of multiple cell lines was another 
strength to this study.  
This study had a few limitations. Although multiple metastatic phenotypes were 
investigated, the invasion assay failed to work. Invasion assays were attempted with 
wild type HaCaT, SRB-12, and COLO-16 cell lines, but these cells failed to cross the 
Matrigel matrix in the assay and therefore further analysis with transfected cells was not 
performed.  Although multiple candidate miR-31 target genes were evaluated by qPCR, 
most of these genes were not evaluated at the protein level.  Thus, it is possible that 
they are miR-31 targets, but miR-31 binding influences translation and not stability of 
the mRNA. Another limitation was that no experiments were done to test whether there 
is evidence of miR-31 binding to the predicted miR-31 binding sites in LIMK2. Despite 
the results indicating that miR-31 promotes migration, the mechanism behind this 




CHAPTER 7: CONCLUSION AND FUTURE DIRECTIONS 
In conclusion, miR-31 promotes the metastatic phenotype of cell migration, but not cell 
proliferation. This confirms previous results showing an effect of miR-31 on migration in 
SCC cell lines [15].  miR-31 upregulation in cSCC cell lines compared to a normal cell 
line provides circumstantial evidence that miR-31 may promote cancer phenotypes, and 
therefore, more phenotypic assays should be investigated. Of the nine original genes of 
interest, only LIMK2 showed some limited evidence of being downregulated by miR-31 
and only in HaCaT cells. However, as these results were not significant, it cannot be 
said that this is a definitive association. More transfections and quantification of gene 
expression are required.  
Along with more phenotypic assays investigating the role of miR-31 in metastasis and 
LIMK2 expression quantification, future directions should include replicating performed 
experiments in the third, more aggressive COLO-16 cell line. This will provide more 
evidence into miR-31’s role in a cSCC cell line that has high miR-31 expression levels. 
miR-31-mediated regulation of LIMK2 should also be investigated with a luciferase 
reporter gene assay. Also, experiments manipulating LIMK2 expression and observing 
change in phenotypes will give greater insight into LIMK2’s part in metastasis and 
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